Gemcitabine Alone versus combination of Gemcitabine and Cisplatin for the Treatment of Patients with Locally Advanced and/or Metastatic Pancreatic Carcinoma: A Retrospective Analysis of multicenter study

Neoplasma

Volumn 59, Issue 3, 2012, Pages 297-301

  Inal, A ^a   Kos, F T ^b   Algin, E ^c   Yildiz, R ^d   Dikiltas, M ^e   Unek, I T ^f   Colak, D ^g   Elkiran, E T ^h   Helvaci, K ⁱ   Geredeli, C ^j   Dane, F ^k   Balakan, O ^l   Kaplan, M A ^a   Durnali, A G ⁱ   Harputoglu, H ^m   Goksel, G ⁿ   Ozdemir, N ^b   Buyukberber, S ^c   Gumus, M ^d   Kucukoner, M ^a   Ozkan, M ^e   Uncu, D ^b   Benekli, M ^c   Isikdogan, A ^a   more..

^a DICLE UNIVERSITY   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c GAZI UNIVERSITY   (Turkey)

^d DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^e ERCIYES UNIVERSITY   (Turkey)

^f DOKUZ EYLUL UNIVERSITY   (Turkey)

^g DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

^h FIRAT UNIVERSITY   (Turkey)

ⁱ Dr Abdurrahman Yurtaslan Education and Research Hospital   (Turkey)

^j Secuk University   (Turkey)

^k MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^l GAZIANTEP UNIVERSITY   (Turkey)

^m INONU UNIVERSITY   (Turkey)

ⁿ CELAL BAYAR UNIVERSITY   (Turkey)

more..

Author keywords

Advanced pancreatic cancer; Cisplatin; First line chemotherapy; Gemcitabine

Indexed keywords

CISPLATIN; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CARCINOMA; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ADENOCARCINOMA; CANCER STAGING; CLINICAL TRIAL; FOLLOW UP; LYMPH NODE METASTASIS; MORTALITY; MULTICENTER STUDY; PANCREAS TUMOR; PATHOLOGY; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84863844209     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2012_038     Document Type: Article

References (18)

1. JEMAL A, SIEGEL R, WARD E, HAO Y, XU J, et al. Cancer statistics, 2009. 2009 Jul-Aug;59: 225-49.
2. ROYAL RE, WOLFF RA, CRANE CH. Cancer of the pancreas. In: DeVita VT, Hellman S, Rosenberg SA editors. Cancerprinciples and practice of oncology. 9th ed. Philadelphia: Lippincott and Wilkins; 2011p. 961-989.
3. LI D, XIE K, WOLFF R, ABBRUZZESE JL. Pancreatic cancer. Lancet. 2004 Mar 27; 363: 1049-57. http://dx.doi.org/10.1016/S0140-6736(04)15841-8
4. National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology: Pancreatic adenocarcinoma version 2.2012. Fort Washington, PA, National Comprehensive Cancer Network, 2012.
5. PETERS GJ, BERGMAN AM, RUIZ VAN HAPEREN VW, VEERMAN G, KUIPER CM, et al: Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995, 22: 72-79.
6. BERGMAN AM, RUIZ VAN HAPEREN VWT, VEERMAN G, KUIPER CM, PETERS GJ. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996; 2: 521-30.
7. HEINEMANN V, LABIANCA R, HINKE A, LOUVET C. Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: Pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol. 2007, 18: 1652-1659. http://dx.doi.org/10.1093/annonc/mdm283
8. HEINEMANN V, QUIETZSCH D, GIESELER F, GONNERMANN M, SCHONEKAS H, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24: 3946-3952. http://dx.doi.org/10.1200/JCO.2005.05.1490
9. LOUVET C, LABIANCA R, HAMMEL P, LLEDO G, ZAMPINO MG, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23: 3509-3516. http://dx.doi.org/10.1200/JCO.2005.06.023
10. VIRET F, YCHOU M, LEPILLE D, MINEUR L, NAVARRO F, et al. Gemcitabine in combination with cisplatin versus gemcitabine alone in the treatment of locally advanced or metastatic pancreatic cancer: final results of a multicenter randomized phase II study. Proc Am Soc Clin Oncol 2004: 22 (Abstr 4118).
11. COLUCCI G, GIULIANI F, GEBBIA V, BIGLIETTO M, RABITTI P, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologico dell'Italia Meridionale. Cancer 2002; 94: 902-910. http://dx.doi.org/10.1002/cncr.10323.abs
12. THERASSE P, ARBUCK SG, EISENHAUER EA, WANDERS J, KAPLAN RS, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-16. http://dx.doi.org/10.1093/jnci/92.3.205
13. HEINEMANN V. Gemcitabine-based combination treatment of pancreatic cancer. Semin Oncol 2002; 29: 25-35. http://dx.doi.org/10.1053/sonc.2002.30749
14. POPLIN E, LEVY DE, BERLIN J, ROTHENBERG ML, HOCHSTER H, et al. Phase III trial of gemcitabine (fixeddose rateinfusion [FDR]) versus gemcitabine plus oxaliplatin (GEMOX) in patients with advanced pancreatic cancer. J Clin Oncol. 2006; 24: 933.
15. CASCINU S, LABIANCA R, CATALANO V, BARNI S, FERRAU F et al. Weekly gemcitabine and cisplatin chemotherapy: A well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients-Areport from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann Oncol. 2003, 14: 205-208. http://dx.doi.org/10.1093/annonc/mdg061
16. HEINEMANN V, WILKE H, MERGENTHALER HG, CLEMENS M, KONIG H, et al. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 2000, 11: 1399-1403. http://dx.doi.org/10.1023/A:1026595525977
17. PHILIP PA, ZALUPSKI MM, VAITKEVICIUS VK, ARLAUSKAS P, CHAPLEN R, et al. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer. 2001, 92: 569-577. http://dx.doi.org/10.1002/1097-0142(20010801)92:3<569::AIDCNCR1356>3.0.CO;2-D
18. BURRIS HA, MOORE MJ, ANDERSEN J, GREEN MR, ROTHENBERG ML, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 1997, 15: 2403-2413.